Navigation Links
Inovio Pharmaceuticals to Present at American Society of Gene & Cell Therapy Annual Meeting May 18 - 21, 2011
Date:5/17/2011

herapies and the promotion of professional and public education in the field.

About Inovio Pharmaceuticals, Inc. Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. Its SynCon™ vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio's proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio clinical programs include three Phase II studies for vaccines treating cervical dysplasia/cancer, hepatitis C virus, and leukemia. Other clinical programs target influenza (preventive) and HIV (preventive and therapeutic). Inovio partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
2. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
3. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
4. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
5. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
6. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
7. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
8. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
9. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
10. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
11. Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... NEW YORK , Feb. 27, 2015 ... investigating the board of Salix Pharmaceuticals, Ltd. (NASDAQ: ... only $158.00 per share. Concerned SLXP investors are encouraged ... . The investigation focuses upon the ... proposed agreement, Salix shareholders would receive only $158.00 per ...
(Date:2/27/2015)... Mass. , Feb. 27, 2015  Boston Scientific ... participate in the Barclays 2015 Annual Healthcare Conference on ... Dan Brennan , executive vice president ... vice president, Investor Relations, will participate in a 25-minute ... host analyst at approximately 1:05 p.m. ET. Following a ...
(Date:2/27/2015)... - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), ... for its first quarter ended December 31, 2014. ... 2014, revenue was $1,336,685. Operating expenses were $1,063,393.  Net ... share.  Covalon,s President and CEO, ... the significant progress we have made over the past ...
Breaking Medicine Technology:Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3
... PHILADELPHIA, Pa. June 20 GlaxoSmithKline,(NYSE: GSK ... and Drug,Administration has extended the priority review period ... treated patients,with chronic idiopathic thrombocytopenic purpura, as they ... Drug User Fee action date has,been extended to ...
... OAK LAWN, Ill., June 20 Advocate Christ,Medical Center ... a few institutions,in the Chicago area, the only one ... hospitals nationally that are using a glue-like liquid for,the ... a recent two-and-a-half-hour procedure, Thomas J. Grobelny MD, of,the ...
Cached Medicine Technology:GSK Update on FDA Review of Promacta(R) (Eltrombopag) 2Advocate Christ Medical Center Using Glue-Like Liquid to Seal Off Brain Aneurysms 2
(Date:3/1/2015)... March 02, 2015 As residents ... works co-founders, Michael Burns and Carita Weaver, believe ... to working with the Southlake Chamber of Commerce, ... web works recently launched a website for Southlake ... A primary communications tool for Hill’s campaign, the ...
(Date:3/1/2015)... (PRWEB) March 01, 2015 Adults who ... insurance rates for term or universal policies can now ... of the best life insurance companies for single adults ... system at http://quotespros.com/life-insurance.html . , The rate plans ... portal are tied to a number of life protection ...
(Date:3/1/2015)... 2015 The number of transvaginal mesh ... past few weeks in two New Jersey litigations where ... the Firm announces. , A Case List updated ... Bergen County proceeding established for products manufactured by Johnson ... weeks earlier, when 90 fewer cases had been centralized. ...
(Date:3/1/2015)... March 01, 2015 Theme and plugin ... transition pack for Final Cut Pro X ... style transitions to any FCPX editors project.” Said Christiana ... users the tools needed to easily drag and drop ... user gets many different controls over the parameters of ...
(Date:2/28/2015)... TX (PRWEB) March 01, 2015 Heart ... estimated that 10 percent of urban adult population and ... form of heart diseases and 20-30 percent of them ... to heart ailments and coronary vascular diseases (CVD). , ... launched a new market research report titled “Indian Coronary ...
Breaking Medicine News(10 mins):Health News:Website Launched for Southlake, Texas Mayoral Candidate Laura Hill 2Health News:Best Life Insurance Companies for Single Adults Now Searchable at Insurance Website 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 4Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3
... drug cocktail might be the right mix to fight ... Details of a new study supporting this approach suggest ... work again. The findings were presented today at the ... involves post-menopausal women whose advanced breast cancers are fueled ...
... STATION A gene commonly studied by cancer researchers has been ... Understanding how the gene works means scientists may ... to a study by Texas AgriLife Research appearing in the ... we understand the mechanism, or how the gene works, we believe ...
... new vaccines, safety monitoring and improved federal coordination ... and better coordination are needed to develop vaccines for ... new U.S. report says. , The report, from the ... Vaccine Plan. It cites a need to speed up ...
... GAINESVILLE, Fla., Dec. 11 For more than 400 ... salamanders, trying to understand how these creatures routinely repair ... paralyzed -- or worse. , Now, fueled by a ... of $2.4 million, a multi-institutional team of researchers associated ...
... The controversy over Sen. Harry Reid,s (D-Nev.) request ... purportedly to attend a fundraiser in New Orleans exemplifies ... watchdogs said today. The groups criticized the money-driven political ... time fundraising when they should be addressing the critical ...
... DALLAS, Dec. 11 For their unique Return to ... more active cardiac patients, the Cardiac Rehabilitation program at ... Hospital was recently awarded the Innovation Award from the ... award acknowledges programs that have enhanced their delivery of ...
Cached Medicine News:Health News:Clinical trial advances new approach to re-sensitizing breast cancer 2Health News:Study shows how gene action may lead to diabetes prevention, cure 2Health News:Better Vaccine Planning Needed, Committee Finds 2Health News:Better Vaccine Planning Needed, Committee Finds 3Health News:Effort to Regenerate Injured Spinal Cords Turns to a New Model 2Health News:Effort to Regenerate Injured Spinal Cords Turns to a New Model 3Health News:Effort to Regenerate Injured Spinal Cords Turns to a New Model 4Health News:Controversy Over Reid Fundraiser Exemplifies Need for Fair Elections 2Health News:Baylor Hamilton Heart Hospital Honored for Innovative Rehabilitation Program 2Health News:Baylor Hamilton Heart Hospital Honored for Innovative Rehabilitation Program 3
Our high quality therapeutic drug monitoring reagents, calibrators and controls are available for most chemistry analyzers. Reproducible and accurate results for your laboratory needs....
The Emit 2000 Digoxin Assay is a homogeneous enzyme immunoassay intended for use in the quantitative analysis of digoxin in human serum or plasma. Emit 2000 assays are designed for use with most chem...
The Emit 2000 Digoxin Calibrators are intended for use with the Emit 2000 Digoxin Assay....
... At Akers, our ultimate goal is ... early detection and immediate treatment. Each year ... suffer and die from late detection or ... lives and cripple nations., ,By developing, manufacturing ...
Medicine Products: